Lyndra Therapeutics and Thermo Fisher Scientific have entered a strategic partnership to develop Lyndra's long-acting oral therapies for conditions such as schizophrenia and bipolar disorder.

Lyndra will utilise Thermo Fisher's worldwide clinical research and commercial manufacturing services for its therapies, including its lead investigational product, oral weekly risperidone (LYN-005).

LYN-005 recently achieved its primary endpoint in the pivotal Phase III STARLYNG-1 trial, showcasing its efficacy against daily risperdal.

The partnership will leverage Thermo Fisher's accelerator drug development services, which offer a suite of manufacturing, clinical research and clinical supply chain services.

The services are tailored to support biotech and pharmaceutical companies from pre-clinical stages to commercialisation.

Lyndra aims to harness Thermo Fisher's pharmaceutical manufacturing capabilities in Cincinnati in the US state of Ohio. This includes the commercial line for Lyndra's LYNX drug delivery platform, which will facilitate the manufacturing of commercial materials at scale.

The platform is tailored to enhance clinical outcomes by optimising the delivery of oral medicines.          

The technology underpinning the LYNX platform was developed in the Traverso and Langer Laboratories, from which Lyndra has an exclusive technology licence.

The partnership also opens opportunities for other pharmaceutical partners interested in creating long-acting oral therapies using LYNX platform technology.

Lyndra Therapeutics global product development president and chief medical officer Dr Richard Scranton stated: “Lyndra’s clinical research and manufacturing collaboration with Thermo Fisher is a critical step in our mission to transform how patients take medicine, providing the capabilities and scale to bring long-acting oral therapies to broad markets.

“Thermo Fisher will be part of our ecosystem of best-in-class partners as we execute our go-to-market strategy, allowing Lyndra to focus on what we do best – research and development for innovative long-acting oral therapeutic solutions – while ensuring reliable, scalable manufacturing and clinical trial operations.”

In December 2023, Lyndra secured $101m in Series E financing to advance its pipeline of long-lasting oral therapy products.